NRXS.AMEXNeuraxis, INC
10-Q: Neuraxis Q2 2025: Revenue Up, Losses Narrow, Capital Raised
Sentiment:
Quarterly Report
Neuraxis, Inc. reported increased net sales and a reduced net loss for Q2 2025, bolstered by a significant capital raise, despite ongoing operational losses and a 'going concern' warning.
Capital raiseIssued 1,538,461 shares of common stock for gross proceeds of $4,999,999 pursuant to a securities purchase agreement with institutional investors.Generated $1,002,991 from the exercise of common stock warrants.The company explicitly states its intention to fund future operations through 'additional dilutive or nondilutive financing'.
Better than expectedNet sales increased significantly by 42.3% for the six months ended June 30, 2025.Net loss decreased by 21.2% for the six months ended June 30, 2025, indicating a reduction in losses.Operating loss also decreased for both the three and six-month periods.Cash and working capital positions improved substantially due to successful financing activities.A major lawsuit was settled, removing a significant contingent liability.
Summary
- Net sales for the six months ended June 30, 2025, increased by 42.3% to $1,789,741, up from $1,258,135 in the prior year period.
- Net loss for the six months ended June 30, 2025, decreased by 21.2% to $3,969,102, compared to $5,038,361 for the same period in 2024.
- Gross profit for the six months ended June 30, 2025, rose by 35.5% to $1,503,623, but gross margin declined to 84.0% from 88.2% due to higher discounting and expired RED inventory.
- Cash and cash equivalents increased to $5,988,456 as of June 30, 2025, from $3,696,870 at December 31, 2024, primarily due to financing activities.
- Approximately $5 million was raised through the issuance of common stock and over $1 million from warrant exercises.
- A $750,000 settlement was reached for a pending lawsuit, payable in 12 equal monthly installments beginning in January 2026.
- The license for the NSS-2 Bridge device was terminated with Masimo Corporation for $200,000, allowing Neuraxis to recapture rights to the trademark and patent applications.
- Management identified material weaknesses in internal control over financial reporting, with remediation efforts ongoing.
- Auditors expressed substantial doubt about the company's ability to continue as a going concern due to historical losses and negative cash flows from operations.
Sentiment
Score: 6
Explanation: While the company showed strong revenue growth and a reduction in net loss, coupled with a successful capital raise, the persistent 'going concern' warning and identified material weaknesses in internal controls temper the overall positive sentiment. The strategic recapture of IP and new product launches are positive, but the underlying profitability challenge remains significant.
Positives
- Net sales increased significantly by 42.3% for the six months ended June 30, 2025, driven by volume growth and the launch of the RED product.
- Net loss decreased by 21.2% for the six months ended June 30, 2025, indicating improved financial performance compared to the prior year.
- Operating loss decreased by 22.2% for the three months ended June 30, 2025, and slightly for the six months ended June 30, 2025, reflecting better cost management in some areas.
- Cash and cash equivalents increased to $5,988,456 and working capital to $4,271,446 as of June 30, 2025, primarily from successful financing activities.
- Successful capital raise of nearly $5 million through common stock issuance and over $1 million from warrant exercises.
- Recaptured rights to the NSS-2 Bridge trademark and patent applications by terminating the license with Masimo, providing future strategic flexibility.
- Settlement of a significant lawsuit for $750,000, resolving a long-standing legal proceeding.
Negatives
- Gross margin decreased to 84.0% for the six months ended June 30, 2025, from 88.2% in the prior year, attributed to higher discounting in patient assistance programs and expired RED inventory.
- Selling expenses increased significantly by 94.1% for the six months ended June 30, 2025, due to higher sales volume and a temporary commission structure.
- Research and development expenses increased by 80.4% for the six months ended June 30, 2025, due to medical research projects and RED device development costs.
- Net cash used in operating activities increased by 4.2% for the six months ended June 30, 2025, indicating a higher cash burn from core operations.
- Accrued preferred stock dividends totaled $421,008 for the six months ended June 30, 2025, which are cumulative and can be paid in cash or common stock.
- The company continues to incur significant operating losses and has negative cash flows from operations since inception.
Risks
- Substantial doubt about the company's ability to continue as a going concern due to historical losses and negative cash flows from operations.
- Future capital requirements are significant and depend on progress in developing, manufacturing, and marketing technologies, patent enforcement, collaborative arrangements, and market developments.
- Ability to generate sufficient revenue and achieve profitability is dependent on successfully marketing products and securing purchase orders, particularly widespread insurance coverage for IB-Stim.
- Ongoing legal proceedings, including a threatened lawsuit regarding a patent interest valued at $2,000,000, which remains unresolved.
- Material weaknesses identified in internal control over financial reporting, including ineffective approval processes, inadequate contract management, misapplication of U.S. GAAP, and ineffective disclosure controls.
- Reliance on two third-party manufacturers for medical devices.
- Potential for fluctuations in gross margin due to changes in average selling prices, patient healthcare coverage mix (discounts), and new product introductions.
- Exposure to interest rate risk on promissory notes.
- Two demand notes receivable from shareholders ($1,012,800 principal) have a full allowance for collection risk, indicating uncollectible related-party debt.
Future Outlook
The company expects to incur significant expenses and operating losses for the foreseeable future as it pursues widespread insurance coverage for its IB-Stim device and seeks FDA clearance for new indications, including functional nausea, post-concussion syndrome, and cyclic vomiting syndrome in children. Future profitability is dependent on achieving sufficient revenues to support its cost structure, primarily through broader insurer acceptance and new product approvals. The company intends to fund future operations through additional dilutive or non-dilutive financing.
Management Comments
- Our ability to generate revenue and achieve profitability requires us to successfully market and secure purchase orders for our products from customers currently identified in our sales pipeline and to new customers as well.
- The primary activity that will drive all customers and revenues is the adoption of insurance coverage by commercial insurance carriers nationally, which is a top priority of the Company.
- Management is committed to maintaining a strong internal control program over financial reporting and will take further actions and implement additional enhancements or improvements as necessary.
- We believe the Company has meritorious defenses and intends to defend this matter vigorously.
Industry Context
Neuraxis operates in the neuromodulation medical device sector, focusing on pediatric and adult conditions like IBS and chronic constipation. The company's strategy to expand insurance coverage for its IB-Stim device and seek new FDA clearances for conditions like functional nausea and post-concussion syndrome aligns with a broader industry trend of expanding indications for existing technologies and addressing unmet needs in specialized patient populations. The termination of the NSS-2 Bridge license and recapture of related IP suggests a strategic focus shift towards core products and direct control over key assets, potentially indicating a move away from licensing models for certain products.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Operating Officer | Unknown | N/A | 2024-04-10 | Employment terminated. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Control Weaknesses Identified | Identified material weaknesses in internal control over financial reporting, including ineffective approval processes, inadequate contract management, misapplication of U.S. GAAP, and ineffective disclosure controls. | 2025-06-30 | Raises concerns about financial reporting reliability and compliance, requiring significant remediation efforts and management time. |
| Internal Control Remediation Efforts | Hiring of a principal financial officer and other accounting personnel, implementation of a documented internal control framework, documentation of business policies (e.g., delegation of authority), completion of a formal monthly close process, and engagement of a third-party firm for segregation of duties. | Ongoing in 2025 | Aimed at enhancing the company's internal control environment and addressing identified material weaknesses, crucial for public company compliance. |
| Employee Stock Purchase Plan Adoption | Adopted the 2025 Employee Stock Purchase Plan (ESPP) to allow eligible employees to acquire common stock at a 15% discount, subject to shareholder approval. | 2025-07-01 | Aims to incentivize and retain employees by offering equity ownership, potentially aligning employee interests with shareholder value. |
Legal Proceedings
- Lawsuit initiated by Ritu Bhambhani, M.D., on February 6, 2019, alleging RICO Act violations, fraudulent misrepresentation, and civil conspiracy related to NeuroStim device billing. The Fourth Circuit Court of Appeals denied the plaintiffs' appeal and entered judgment against them on June 3, 2024, with the mandate effective June 25, 2024.
- Lawsuit initiated by Ritu Bhambhani, LLC and other business entities on July 14, 2022, with similar claims to the 2019 lawsuit, seeking compensatory damages in excess of $75,000. A tentative $750,000 settlement was reached on April 25, 2025, and the settlement agreement was executed on May 15, 2025, with payments starting January 2026.
- Threatened litigation from Dr. Arturo Taca in January 2024, asserting an interest in U.S. Patent No. 10,413,719, valued at $2,000,000. The company denied the claims and intends to vigorously defend the matter.
Related Party Transactions
- Two demand notes receivable from shareholders, each with a principal balance of $506,400, totaling $1,012,800, with no payments received and a full allowance for collection risk.
- Exclusive, worldwide, non-transferable, royalty-free license for auricular patents from a limited liability company in which the CEO and Chief Regulatory, Compliance and Privacy Officer maintain an ownership interest. The company pays maintenance costs (e.g., $1,317 for six months ended June 30, 2025).
- Sales of IB-STIM devices to a Board of Directors member for research and development activities, totaling $6,351 for the six months ended June 30, 2025.
- Accounting and tax services provided by a third-party public accounting firm, where the company's former Chief Financial Officer was the managing partner and majority shareholder. Services totaled $31,679 for the six months ended June 30, 2025.
- Issued 20,000 common shares with a fair value of $55,600 to the former Chief Financial Officer on June 28, 2024, for services rendered during the IPO process.
Stakeholder Impact
- Shareholders: Experienced dilution from recent common stock issuance and face potential future dilutive financing. The improved cash position and reduced net loss are positive, but the 'going concern' warning and material weaknesses in internal controls pose ongoing risks. Series B Preferred Stockholders have cumulative dividends and liquidation preference.
- Employees: The adoption of the 2025 Employee Stock Purchase Plan offers a new incentive for equity ownership. The termination of the COO's employment involved severance payments.
- Customers: The launch of the RED device expands product offerings. Patient Assistance Program and opt-in program for insurance claim payments aim to improve access and affordability for IB-Stim.
- Creditors: The company has promissory notes and convertible notes representing debt obligations. The settlement of a lawsuit reduces a significant contingent liability.
- Suppliers/Manufacturers: The company continues to rely on two third-party manufacturers for its devices.
Next Steps
- Pursue widespread insurance coverage by commercial carriers nationally for the IB-Stim device.
- Seek FDA clearance for the IB-Stim device for other indications, including functional nausea, post-concussion syndrome, and cyclic vomiting syndrome in children.
- Fund sales and marketing efforts to expand the adoption of the RED device.
- Continue remediation efforts and testing of internal controls over financial reporting in fiscal year 2025.
- Receive $100,000 payment from Masimo Corporation on December 31, 2025, and June 30, 2026, for NSS-2 Bridge license termination.
- Begin receiving $750,000 lawsuit settlement payments in 12 equal monthly installments starting January 2026.
- Seek shareholder approval for the 2025 Employee Stock Purchase Plan by July 1, 2026.
- Relocate office space to Batesville, Indiana, effective August 1, 2025.
Key Dates
| Date | Description |
|---|---|
| 2019-02-06 | Plaintiff Ritu Bhambhani, M.D., initiated a lawsuit against Innovative Health Solutions, Inc. (now Neuraxis, Inc.). |
| 2022-01-01 | Lease for office space in Versailles, Indiana commenced. |
| 2022-07-14 | Plaintiffs Ritu Bhambhani and Sudhir Rao filed a notice of appeal with the Fourth Circuit Court of Appeals after summary judgment was granted against them. |
| 2022-07-14 | Plaintiffs Ritu Bhambhani, LLC; Box Hill Surgery Center, LLC; Pain and Spine Specialists of Maryland, LLC; and SimCare ASC, LLC initiated a lawsuit against the Company (the 2022 Lawsuit). |
| 2022-10-01 | Employment agreements with certain key employees commenced. |
| 2023-04-30 | Company amended employee agreements to clarify special incentive payments and deferred bonuses. |
| 2023-11-08 | Company entered into a Securities Purchase Agreement (SPA) with a shareholder for Series B Convertible Preferred Stock. |
| 2024-01-01 | New lease for office space in Carmel, Indiana commenced. |
| 2024-01-02 | First installment of special bonus payments to key employees for stock options began. |
| 2024-01-31 | Dr. Arturo Taca served notice asserting an interest in U.S. Patent No. 10,413,719. |
| 2024-02-11 | Shelf registration statement on Form S-3 (File No. 333-283798) was declared effective by the SEC. |
| 2024-02-12 | Company amended the SPA to issue a convertible promissory note due to delay in stockholder approval for Series B Preferred Stock. |
| 2024-03-18 | Company terminated private placement services agreement and entered into an advisory agreement for debt, equity, and public securities market services. |
| 2024-04-04 | Board approved the issuance of 53,063 common shares to settle a 2023 convertible note dispute. |
| 2024-04-10 | Employment of the Chief Operating Officer was terminated. |
| 2024-06-03 | Fourth Circuit denied plaintiffs' appeal and entered judgment against them in the 2019 lawsuit. |
| 2024-06-25 | Fourth Circuit entered its mandate, making its judgment against the plaintiffs effective. |
| 2024-06-28 | Company issued 90,032 shares of common stock to pre-IPO Series A Preferred Stock shareholders to settle claims. |
| 2024-08-09 | Company entered into a $210,000 promissory note to finance business insurance premiums. |
| 2024-08-15 | Company's shareholders authorized 5,000,000 shares of preferred stock, designating 4,000,000 as Series B preferred stock. |
| 2024-08-15 | Outstanding principal balance of $4,935,000 from Amended 2024 Convertible Promissory Notes was mandatorily converted into 2,073,524 Series B Preferred Shares. |
| 2024-11-01 | Company entered into a second promissory note for $64,328 to finance other business insurance policies. |
| 2024-11-11 | Company's shareholders authorized an increase in designated Series B Preferred Stock to 5,000,000 shares and extended the cumulative dividend period to December 31, 2026. |
| 2024-12-31 | Company and financial advisor terminated the advisory agreement. |
| 2025-01-03 | Company initiated grants of restricted stock units (RSUs) to certain employees. |
| 2025-01-17 | Company issued common stock to Board of Directors for service and to an investor in a cashless warrant exercise. |
| 2025-04-25 | Parties reached a tentative $750,000 settlement for the 2022 lawsuit. |
| 2025-05-15 | Settlement agreement for the 2022 lawsuit was duly executed. |
| 2025-05-19 | Company terminated its lease in Versailles, Indiana, effective July 31, 2025. |
| 2025-05-20 | Company issued 342,016 shares of common stock upon conversion of Series B Preferred Stock. |
| 2025-05-21 | Company issued 430,580 shares of common stock upon exercise of warrants for $1,002,962. |
| 2025-05-22 | Company issued 1,538,461 shares of common stock for $4,999,999 pursuant to a securities purchase agreement. |
| 2025-05-26 | Company entered into a third promissory note for $122,253 to finance software subscription fees. |
| 2025-06-09 | Company issued 42,016 shares of common stock upon conversion of Series B Preferred Stock. |
| 2025-06-09 | Promissory note from August 9, 2024, matured. |
| 2025-06-30 | End of the reported quarterly period. |
| 2025-07-01 | Company terminated the NSS-2 Bridge license with Masimo Corporation. |
| 2025-07-01 | Compensation Committee adopted the NeurAxis, Inc. 2025 Employee Stock Purchase Plan (ESPP). |
| 2025-07-31 | Lease in Versailles, Indiana, terminated. |
| 2025-08-01 | Relocation of office space to Batesville, Indiana, effective. |
| 2025-08-12 | Date of filing of the Quarterly Report on Form 10-Q. |
| 2025-09-01 | Second promissory note from November 1, 2024, matures. |
| 2025-12-31 | First installment of $100,000 from Masimo Corporation due. |
| 2026-01-01 | First installment of $750,000 lawsuit settlement due. |
| 2026-06-30 | Second installment of $100,000 from Masimo Corporation due. |
| 2026-12-31 | Extended cumulative dividend period for Series B Preferred Stock expires. |
| 2027-03-01 | Third promissory note from May 26, 2025, matures. |
| 2028-08-08 | Expiration date for Underwriter Warrants. |
| 2028-09-18 | Expiration date for Investor Warrants. |
| 2029-12-31 | Various expiration dates for Advisory Agreement Warrants. |
| 2035-01-01 | Annual increase period for ESPP shares ends. |
| 2037-10-18 | Exclusive license agreement for auricular patents expires. |
Recommendation
holdWhile Neuraxis demonstrated strong revenue growth and a notable reduction in net loss, coupled with a successful capital raise that significantly improved its cash position, the persistent 'going concern' warning from auditors and identified material weaknesses in internal controls present substantial risks. The company's long-term profitability remains contingent on securing widespread insurance coverage and new FDA clearances, which are uncertain. The positive operational improvements and capital infusion provide a lifeline, but the fundamental challenges of achieving sustainable profitability and resolving internal control issues warrant a cautious 'hold' stance. Investors should monitor progress on insurance adoption, R&D milestones, and internal control remediation before considering further investment.
Keywords
Neuromodulation, Medical Devices, IB-STIM, Rectal Expulsion Device, RED Device, Functional Abdominal Pain, Irritable Bowel Syndrome, IBS, Chronic Constipation, Pelvic Floor Dyssynergia, FDA Cleared, Healthcare Technology, SEC Filing, Quarterly Report, NRXS, Biotechnology, MedTech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.